DLA PIPER LLP (US) lobbying for NOVARTIS

Filing Registration

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jun 24, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 5

RICHARD BURR Former member of Congress New on this filing

Previously held: U.S. Senator
RACHEL PORTMAN New on this filing

Previously held: Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman
MARGARET MARTIN New on this filing

Previously held: Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr
MICHAEL SORENSEN New on this filing

Previously held: Scheduler and other positions, Sen. Richard Burr; Intern, Rep. John Boehner; Intern, Rep. Mike Kelly
VINCENT SARUBBI JR New on this filing

Previously held: Deputy Chief of Staff and Legislative Director, Rep. Josh Gottheimer; Legislative Assistant, Sen. Sherrod Brown; Senior Legislative Assistant, Rep. Donald Norcross; Legislative Assistant, Rep. Rob Andrews

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Lobbying activity 2

Pharmacy

Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.

Medical/Disease Research/Clinical Labs

Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.

Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

NOVARTIS INTERNATIONAL AG

Switzerland · CH-4056 Basel · owns 100% of the client · contributed $0.00